The β-D-glucose scaffold as a β-turn mimetic

Accounts of Chemical Research

Volumn 42, Issue 10, 2009, Pages 1511-1520

  Hirschmann, Ralph F ^a   Nicolaou, K C ^b,c   Angeles, Angie R ^a   Chen, Jason S ^b   Smith III, Amos B ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; SOMATOSTATIN;

ANIMAL; ARTICLE; BIOMIMETICS; CHEMISTRY; DRUG DESIGN; HUMAN; METABOLISM;

ANIMALS; BIOMIMETICS; DRUG DESIGN; GLUCOSE; HUMANS; SOMATOSTATIN;

EID: 70350304181     PISSN: 00014842     EISSN: None     Source Type: Journal    
DOI: 10.1021/ar900020x     Document Type: Article

References (57)

1. (a) Veber. D. F.; Sapersteln. R.; Nutt. R. F.; Freldinger. R. M.; Brady. S. F.; Curley. P.; Perlow. D. S.; Paleveda. W. J.; Colton. C. D.; Zacchel. A. G.; Tocco. D. J.; Hoff. D. R.; Vandlen. R. L.; Gerlch. J. E.; Hall. L.; Mandarino. L; Cordes. E. H.; Anderson. P. S.; Hirschmann. R. A Super Active Cyclic Hexapeptlde Analog of Somatostatin. Life Sci. 1984. 34.1371-1378.
2. (b) Veber. D. F.; Freldinger. R. M. The Design of Metabollcally-Stable Peptide Analogs. Trends Neurosei. 1985. 392-396.
3. (c) Stein. W. D. The Movement of Molecules Across Cell Membranes. Academic: New York. 1967; pp 65-125.
4. (d) Diamond. J. M.; Wright. E. M. Molecular Forces Governing Non-Electrolyte Permeation through Cell Membranes. Proc. R. Soc. Ser. B 1969. 172. 273-316.
5. Shemyakln. M. M.; Ovchinnlkov. Y. A.; Ivanov. V. J. Topochemical Investigations on Peptide Systems. Angew Chem., Int. Ed. Enal. 1969. 8. 492-499.
6. (a) Freldinger. R. M.; Perlow. D. S.; Veber. D. F. Protected Lactam-Bridged Dipeptides for Use as Conformational Constraints In Peptides. J. Ora. Chem. 1982. 47.104-109.
7. (b) Pelton. J. T.; Gulya. K.; Hruby. V.; Duckies. S. P.; Yamamura. H. I. Conformatlonally Restricted Analogs of Somatostatin with High .μ-Opiate Receptor Specificity. Proc. Natl Acad. Sci. U.S.A. 1985. 82. 236-239.
8. (c) U. W.; Hanau. C. E.; dAvignon. A.; Moeller. K. D. Conformatlonally Restricted Peptide Mimetics: The Incorporation of 6.5-Blcycllc Lactam Ring Skeletons into Peptides. J. Org. Chem. 1995. 50. 8155-8170.
9. Smith. A B., III.; Keenan. T. P.; Holoomb. R. C.; Sprengeler. P. A.; Guzman. M. C.; Wood. J. L.; Carrol. P. J.; Hirschmann. R. Design. Synthesis. and Crystal Structure of a Pyrrollnone-Based Peptidomlmetic Possessing the Conformation of a β-Strand: Potential Application to the Design of Novel Inhibitors of Proteolytic Enzymes. J. Am. Chem. 1992. 114.10672-10674.
10. Hirschmann. R. Medicinal Chemistry in the Golden Age of Biology. Lessons from Steroid and Peptide Research. Angew. Chem., Int, Ed. Engl. 1991. 30.1278-1301.
11. Sawyer. T. K. In Structure-Based Drug Design: Diseases. Targets. Techniques and Developments; Veerapandlan. P., Ed.; Marcel Dekker: New York. 1997; pp 559- 634.
12. Farmer. P. S. Bridging the Gap between Bloactive Peptides and Nonpeptides: Some Perspectives In Design. In Drug Design; Ariens. E. J., Ed.; Academic: New York. 1980; pp 119-143.
13. Belanger. P. C.; Dufresne. C. Preparation of exo-6-Benzyl-exo-2-(m- Hydroxyphenyl)1 -Dimethylaminomethylbicyclo[2.2.2]octane. A Non-Peptlde Mimic of Enkephalins. Can J. Chem. 1986. 64.1514-1520.
14. Olson. G. L.; Cheung. H.-C.; Chiang. E.; Madison. V. S.; Sepinwall. J.; Vincent. G. P.; Winkokur. A.; Gary. K. A. Peptide Mimetics of Thyrotropin-Releasing Hormone Based on a Cyclohexane Framework: Design. Synthesis. and Cognition-Enhancing Properties. J. Med. Chem. 1995. 38. 2866-2879.
15. (a) Rudinger. J. Design of Peptide Hormone Analogs. In Drug Design; Ariens. E. J., Ed.; Academic Press: New York. 1971 ; Vol.2. pp 319-419.
16. (b) Urry. D. W.; Walter. R. Proposed Conformation of Oxytocin In Solution. Proc. Natl. Acad. Sci. U.S.A. 1971. 68. 956-958.
17. Hughes. J.; Smith. T. W.; Kosterlltz. H. W.; Fothergill. L. A.; Morgan. B. A; Morris. H. R. Identification of Two Related Pentapeptides from the Brain with Potent Opiate Agonist Activity. Nature 1975. 258. 577-579.
18. Eisenmesser. E. Z.; Bosco. D. A.; Akke. M.; Kern. D. Enzyme Dynamics during Catalysis. Science 2002. 295.1520-1523.
19. (a) Blkker. J. A.; Trumpp-Kallmeyer. S.; Humblet. C. G-Protein Coupled Receptors: Models. Mutagenesis. and Drug Design. J. Med Chem. 1998. 41. 2911-2927.
20. (b) Palczewskl. K.; Kumasaka. T.; Hori. T.; Behnke. C. A.; Motoshlma. H.; Fox. B. A.; Le Trong. I.; Teller. D. C.; Okada. T.; Stenkamp. R. E.; Yamamoto. M.; Miyano. M. Crystal Structure of Rhodopsin A: A G Protein-Coupled Receptor. Science2000. 289. 739-745.
21. (a) Nlcolaou. K. C.; Salvlno. J. M.; Raynor. K.; Pletranico. S.; Reislne. T.; Freidinger. R. M.; Hirschmann. R. In Design and Synthesis of a Peptidomlmetic Employingß-DGlucose for Scaffolding; Rivier. J. E., Marshall. G. R., Eds.; ESCOM: Leiden. 1990; pp 881-884.
22. (b) Hirschmann. R.; Nlcolaou. K. C; Pletranico. S.; Salvlno. J.; Leahy. E. M.; Sprengeler. P. A.; Fürst. G.; Smith. A B., III.; Strader. C. D.; Cascleri. M. A.; Candelore. M. R.; Donaldson. C.; Vale. W.; Maechler. L. Nonpeptldal Peptidomimetics with β-D-Glucose Scaffolding. A Partial Somatostatin Agonist Bearing a Close Structural Relationship to a Potent. Selective Substance P Antagonist. J. Am. Chem. 1992. 114. 9217-9218.
23. (c) Hirschmann. R.; Nlcolaou. K. C; Pietranlco. S.; Leahy. E. M.; Salvino. J.; Anson. B.; Cchy. M. A; Spoors. P. G.; Shakespeare. W. C.; Sprengeler. P. A.; Hamley. P.; Smith. A. B., III.; Relsine. T.; Raynor. K.; Maechler. L.; Donaldson. C.; Vale. W.; Freidlnger. R. M.; Cascierl. M. A.; Strader. C. D. De Novo Design and Synthesis of Somatostatin NonPeptide Peptidomimetkics Utilizing β-D-glucose as a Novel Scaffolding. J. Am. Chem. Soc. 1993. 115.12550-12568.
24. (d) Hirschmann. R.; Yao. W. Q.; Cascierl. M. A.; Strader. C. D.; Maechler. L.; Clchy-Knight. M. A; Hynes. J., Jr.; van RiJn, R. D.; Sprengeler. P. A.; Smith. A. B., III. Synthesis of Potent Cyclic Hexapeptide NK-1 Antagonists. Use of a Minilibrary in Transforming a Peptidal Somatostatin Receptor Ugand into an NK-1 Receptor Ugand via a Polyvalent Peptidomimetic. J. Med. Chem. 1996. 39. 2441-2448.
25. Brazeau. P.; Vale. W.; Burgus. R.; Gulllemin. R. Isolation of Somatostatin (a Somatotropin Release Inhibiting Factor) of Ovine Hypothalamic Origin. Can. J. Biochem. 1974.52.1067-1072.
26. Patel. Y. C. Molecular Pharmacology of Somatostatin Receptor Subtypes. J. Endocrinol. Invest. 1997. 20. 348-367.
27. (a) Csaba. Z.; Dournaud. P. Cellular Biology of Somatostatin Receptors. Neuropeptides2001. 35.1-23.
28. (b) Raynor. K.; Relsine. T. Somatostatin Receptors. Crit. Rev. Neurobiol. 1992. 6. 273-289.
29. Reisine. T.; Bell. G. I. Molecular Biology of Somatostatin Receptors. Endocr. Rev. 1995. 16. 427-442.
30. Yamada. Y.; Post. S. R.; Wang. K.; Tager. H. S.; Bell. G. I.; Seino. S. Cloning and Functional Characterization of a Family of Human and Mouse Somatostatin Receptors Expressed in Brain. Gastrointestinal Tract. and Kidney. Proc. Nati. Acad. Sci. U.S.A. 1992. 89. 251-255.
31. 8-Somatostatin. Analog of Somatostatin More Potent than the Native Molecule. Biochim. Biophys, Res,Commun. 1975, 65, 746 751.
32. Veber. D. F.; Holly. F. W.; Paleveda. W. J.; Nutt. R. F.; Bergstrand. S. J.; Torchina. M.; Glizer. M. S.; Saperstein. R.; Hirschmann. R. Conformatinally Restricted Bicyclic Analogs of Somatostatin. Proc, Natl. Acad. Scie. U.S.A. 1978, 2636 2640.
33. Chandrasekaran. R.; Lakshminarayanan. A. V.; Pandya. U. V.; Ramachandran. G. N. Conformation of the LL and LD Hairpin Bends with Internal Hydrogen Bonds In Proteins and Peptides. Bichim Biophys. Acta 1973, 303, 14-27.
34. (a) Vale. W.; Rivier. J.; Ling. N.; Brown. M. Biologic and Immunologic Activities and Applications of Somatostatin Analogs.Metabolism 1978.27.1391-1401.
35. (b) Bauer. W.; Briner. U.; Doepfiner. W.; Haller. R.; Huguenin. R.; Marbach. P.; Petcher. T. J.; Pless. J. SMS 201 -995: A Very Potent and Selective Octapeptlde Analog of Somatostatin with Prolonged Action. life Sci. 1982. 31.1133-1140.
36. (a) Veber. D. F.; Freldinger. R. M.; Perlow. D. S.; Paleveda. W. J. J.; Holly. F. W.; Strachan. R. G.; Nutt. R. F.; Arlson. B. H.; Homnlck. C.; Randall. W. C.; Glitzer. M. S.; Saperstein. R.; Hirschmann. R. A Potent Cyclic Hexapeptide Analog of Somatostatin. Nature 1981. 292 55-58.
37. (b) Veber. D. F.; Holly. F. W.; Nutt. R. F.; Bergstrand. S. J.; Brady. S. F.; Hirschmann. R.; Glitzer. M. S.; Saperstein. R. Highly Active Cyclic and Bicyclic Somatostatin Analogs of Reduced Ring Size. Nature 1979. 250.512-614.
38. Arlson. B. H.; Hirschmann. R.; Paleveda. W. J.; Brady. S. F.; Veber. D. F. On the Low Energy Solution Conformation of Somatostatin. Biochem. Biophys. Res. Commun. 1981. 700.1148-1153.
39. Hirschmann. R. Some Recent Developments In the Chemistry and Biology of Somatostatln-Related Peptides. In Chemistry of Natural Products: Proceedings of the Sino-American Symposium on the Chemistry of Natural Products; Yu. W., Ed. ; Gordon and Breach. Science Publishers: New York. 1982; pp 44-54.
40. Veber. D. F. Design of a Highly Active Cyclic Hexapeptide Analog of Somatostatin. In Peptides. Synthesis. Structure and Function. Proceedings of the 7th American Peptide Symposium; Rich. D. H., Gross. V. J., Eds.; Pierce Chemical Co.: Rockford. IL. 1981; pp 685-694.
41. Lamberts. S. W.; van der Lily. A-J.; de Herder. W. W.; Hofland. L. J. Octreotide. New Engl. J. Med. 1996. 334. 246-254.
42. Freidinger. R. M.; Colton. C. D.; Perlow. D. S.; Whitter. W. L.; Paleveda. W. J.; Veber. D. F. Modified Retro Enantiomers are Potent Somatostatin Analogs. In Peptides. Structure and Function. Proceedings of the 8th American Peptide Symposium; Hruby. V. J., Rich. D., Eds.; Pierce Chemical Co.: Rockford. IL. 1983; pp 349-352.
43. Prasad. V.; Birzin. E. T.; McVaugh. C. T.; van RiJn, R. D.; Rohrer. S. P.; Chicchi. G.; Underwood. D. J.; Thornton. E. R.; Smith. A. B., III.; Hirschmann. R. Effects of Heterocyclic Aromatic Substituants on Binding Affinities at Two Distinct Sites of Somatostatin Receptors. J. Med. Chem. 2003. 46.1858-1869.
44. Hirschmann. R.; Hynes. J., Jr.; Cichy-Knight. M. A.; van Rijn. R. D.; Sprengeler. P. A.; Spoors. P. G.; Shakespeare. W. C.; Pietranico-Cole. S.; Barbosa. J.; Liu. J.; Yao. W. Q.; Rohrer. S.; Smith. A. B., III. Modulation of Receptor and Receptor Subtype Affinities Using Dlasteromeric and Enantiomeric Monosaccharide Scaffolds as a Means to Structural and Biological Diversity. A New Route to Ether Synthesis. J Med. Chem. 1998. 47.1382-1391.
45. Liu. J.; Underwood. D. J.; Cascieri. M. A.; Rohrer. S. P.; Cantin. L-D.; Chicchi. G.; Smith, A. B., III.; Hirschmann. R. Synthesis of a Substance P Antagonist with a Somatostatin Scaffold: Factors Affecting Agonism/Antagonlsm at GPCRs and the Role of Pseudosymmetry. J. Med. Chem. 2000. 43. 3827-3831.
46. Sequence alignment was performed using CLUSTAL W. Thompson. J. D.; Higglns. D. G.; Gibson. T. J. CLUSTAL W: Improving the Sensitivity of Progressive Multiple Sequence Alignment through Sequence Weighting. Position-Specific Gap Penalties and Weight Matrix Choice. Nucleic Acids Res. 1994. 22. 4673-4680.
47. Cascierl. M. A.; Fong. T. M.; Strader. C. D. Identification of Critical Functional Groups within Binding Pockets of G-Protein-Coupled Receptors. Drugs Future 1996. 27.521-627.
48. Evans. B. E.; Rittle. K. E.; Bock. M. G.; DiPardo. R. M.; Freldinger. R. M.; Whitter. W. L.; Lundell. G. F.; Veber. D. F.; Anderson. P. S.; Chang. R. S. L.; Lotti. V. J.; Cerlno. D. J.; Springer. J. P.; Hirshfield. J. Methods for Drug Discovery: Development of Potent. Selective. Orally Effective Cholecystokinin Antagonists. J. Med. Chem. 1988. 31. 2235-2246.
49. (a) Woltersdorf. O. W.; DeSolms. S. J.; Schultz. E. M.; Cragoe. E. J., Jr. (Acylaryloxy)Acetlc Acid Diuretics. 1. (2-Alkyl-and 2.2-Dlalkyl-1-Oxo- 5Indanyloxy)Acetlc Acids. J. Med. Chem. 1977. 20.1400-1408.
50. (b) Baldwin. J. J.; Hirschmann. R.; Engelhardt. E. L.; Pontlcello. G. S.; Sweet. C. S.; Scriablne. A. Approaches to Vasodilating /β-Adrenergic Blocking Agents: Examples of the Dihydrolutidlne Type. J. Med. Chem. 1981.24.628-631. and references cited therein.
51. Szardenings. A. K.; Harris. D.; Lam. S.; Shi. L.; Tien. D.; Wang. Y.; Patel. D. V.; Navre. M.; Campbell. D. A. Rational Design and Combinatorial Evaluation of Enzyme Inhibitor Scaffolds: Identification of Novel Inhibitors of Matrix Metalloproteinases. Chem. 1998. 41. 2194-2200.
52. (a) Mason. J. S.; Morlze. I.; Menard. P. R.; Cheney. D. L.; Hulme. C.; Labaudinlere. R. F. New 4-Point Pharmacophore Method for Molecular Similarity and Diversity Applications: Overview of the Method and Applications. Including a Novel Approach to the Design of Combinatorial Libraries Containing Privileged Substructures. J. Med. Chem. 1999. 42. 3251-3264.
53. (b) Dolle. R. E.; Nelson. K. H., Jr. Comprehensive Survey of Combinatorial Library Synthesis: 1998. J. Comb. Chem. 1999. 7. 235-282.
54. (c) Lewell. X. Q.; Judd. D. B.; Watson. S. P.; Hann. M. M. RECAP-Retrosynthetic Combinatorial Analysis Procedure: A Powerful New Technique for Identifying Privileged Molecular Fragments with Useful Applications in Combinatorial Chemistry. J. Chem. Inf. Comput. Sci. 1998. 38. 511-522.
55. Bemls. G. W.; Murcko. M. A. The Properties of Known Drugs. 1. Molecular Frameworks. J. Med. Chem. 1996. 39. 2887-2893.
56. Nicolaou. K. C.; Pfefferkorn. J. A.; Roecker. A. J.; Cao. G. Q.; Barluenga. S.; Mitchell. H. J. Natural Product-Like Combinatorial Libraries Based on Privileged Structures. 1. General Principles and Solid-Phase Synthesis of Benzopyrans. J. Am. Chem. Soc. 2000. 122. 9939-9953.
57. Mosley. R. T.; Miller. M. D.; Kearsley. S. K.; Prendergast. K.; Underwood. D. J. New Lead Discovery In Drug Development. In Computational Medicine. Public Health and Biotechnology. Witten M., Ed.; World Scientific: Singapore. 1995; pp 101-125.